Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes

British Journal of Haematology

Volumn 167, Issue 3, 2014, Pages 337-345

  Sekeres, Mikkael A ^a   Giagounidis, Aristoteles ^b   Kantarjian, Hagop ^c   Mufti, Ghulam J ^d   Fenaux, Pierre ^e   Jia, Catherine ^f   Yang, Allen S ^f   Platzbecker, Uwe ^g  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b MARIEN HOSPITAL DÜSSELDORF   (Germany)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITÉ PARIS 13   (France)

^f AMGEN INC   (United States)

^g UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Myelodysplastic syndromes; Platelet; Romiplostim; Thrombocytopenia; Thrombopoietin

Indexed keywords

PLACEBO; ROMIPLOSTIM; THROMBOPOIETIN; ANTIANEMIC AGENT; FC RECEPTOR; HYBRID PROTEIN;

AGED; ARTICLE; BONE MARROW BIOPSY; COHORT ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; INSTRUMENT VALIDATION; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MYELODYSPLASTIC SYNDROME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; TREATMENT DURATION; BIOLOGICAL MODEL; BLOOD; BLOOD TRANSFUSION; DRUG EFFECTS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROMES; RISK ASSESSMENT; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; VALIDATION STUDY;

AGED; BLOOD TRANSFUSION; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; HEMATINICS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYELODYSPLASTIC SYNDROMES; PLATELET COUNT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOPOIESIS; THROMBOPOIETIN;

EID: 84912045541     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13037     Document Type: Article

References (26)

1. Broudy, V.C. & Lin, N.L. (2004) AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine, 25, 52-60.
2. Bussel, J.B., Kuter, D.J., George, J.N., McMillan, R., Aledort, L.M., Conklin, G.T., Lichtin, A.E., Lyons, R.M., Nieva, J., Wasser, J.S., Wiznitzer, I., Kelly, R., Chen, C.F. & Nichol, J.L. (2006) AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. New England Journal of Medicine, 355, 1672-1681.
3. Cheson, B.D., Bennett, J.M., Kantarjian, H., Pinto, A., Schiffer, C.A., Nimer, S.D., Lowenberg, B., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Wijermans, P.W., Gore, S. & Greenberg, P.L. (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood, 96, 3671-3674.
4. Cheson, B.D., Greenberg, P.L., Bennett, J.M., Lowenberg, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Gore, S.D., Schiffer, C.A. & Kantarjian, H. (2006) Clinical application and proposal for modification of theInternational Working Group (IWG) response criteria in myelodysplasia. Blood, 108, 419-425.
5. Fenaux, P., Kantarjian, H.M., Muus, P., Lyons, R.M., Larson, R.A., Sekeres, M.A., Becker, P.S., Jia, C. & Yang, A.S. (2011) Update of an open-label extension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients with myelodysplastic syndromes (MDS). Blood (ASH Annual Meeting Abstracts), 118, 2772.
6. Finch, C.A. (1982) Erythropoiesis, erythropoietin, and iron. Blood, 60, 1241-1246.
7. Garcia-Manero, G., Shan, J., Faderl, S., Cortes, J., Ravandi, F., Borthakur, G., Wierda, W.G., Pierce, S., Estey, E., Liu, J., Huang, X. & Kantarjian, H. (2008) A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia, 22, 538-543.
8. Giagounidis, A., Mufti, G.J., Fenaux, P., Sekeres, M.A., Szer, J., Platzbecker, U., Kuendgen, A., Gaidano, G., Wiktor-Jedrzejczak, W., Hu, K., Woodard, P., Yang, A.S. & Kantarjian, H.M. (2014) Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer, 120, 1838-1846.
9. Gonzalez-Porras, J., Cordoba, I., Such, E., Nomdedeu, B., Vallespi, T., Carbonell, F., Luño, E., Ardanaz, M., Ramos, F., Pedro, C., Gomez, V., de Paz, R., Sanchez-Barba, M., Sanz, G. & Del Cañizo, A. (2011) Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer, 117, 5529-5537.
10. Greenberg, P.L., Garcia-Manero, G., Moore, M., Damon, L., Roboz, G., Hu, K., Yang, A.S. & Franklin, J. (2012a) A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine. Leukemia & Lymphoma, 54, 321-328.
11. Greenberg, P.L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sole, F., Bennett, J.M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., Le Beau, M.M., Slovak, M.L., Krieger, O., Luebbert, M., Maciejewski, J., Magalhaes, S.M., Miyazaki, Y., Pfeilstocker, M., Sekeres, M., Sperr, W.R., Stauder, R., Tauro, S., Valent, P., Vallespi, T., van de Loosdrecht, A.A., Germing, U. & Haase, D. (2012b) Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 120, 2454-2465.
12. Greenberg, P.L., Attar, E., Bennett, J.M., Bloomfield, C.D., De Castro, C.M., Deeg, H.J., Foran, J.M., Gaensler, K., Garcia-Manero, G., Gore, S.D., Head, D., Komrokji, R., Maness, L.J., Millenson, M., Nimer, S.D., O'Donnell, M.R., Schroeder, M.A., Shami, P.J., Stone, R.M., Thompson, J.E. & Westervelt, P. (2013) Myelodysplastic syndromes. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 11, 838-874.
13. Hellstrom, E., Birgegard, G., Lockner, D., Helmers, C., Ost, A. & Wide, L. (1991) Treatment of myelodysplastic syndromes with recombinant human erythropoietin. European Journal of Haematology, 47, 355-360.
14. Hellstrom-Lindberg, E., Negrin, R., Stein, R., Krantz, S., Lindberg, G., Vardiman, J., Ost, A. & Greenberg, P. (1997) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. British Journal of Haematology, 99, 344-351.
15. Hellstrom-Lindberg, E., Gulbrandsen, N., Lindberg, G., Ahlgren, T., Dahl, I.M., Dybedal, I., Grimfors, G., Hesse-Sundin, E., Hjorth, M., Kanter-Lewensohn, L., Linder, O., Luthman, M., Lofvenberg, E., Oberg, G., Porwit-MacDonald, A., Radlund, A., Samuelsson, J., Tangen, J.M., Winquist, I. & Wisloff, F. (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology, 120, 1037-1046.
16. Kantarjian, H., Giles, F., List, A., Lyons, R., Sekeres, M.A., Pierce, S., Deuson, R. & Leveque, J. (2007) The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer, 109, 1705-1714.
17. Kantarjian, H., O'Brien, S., Ravandi, F., Cortes, J., Shan, J., Bennett, J.M., List, A., Fenaux, P., Sanz, G., Issa, J.P., Freireich, E.J. & Garcia-Manero, G. (2008) Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer, 113, 1351-1361.
18. Kantarjian, H., Fenaux, P., Sekeres, M.A., Becker, P.S., Boruchov, A., Bowen, D., Hellstrom-Lindberg, E., Larson, R.A., Lyons, R.M., Muus, P., Shammo, J., Siegel, R., Hu, K., Franklin, J. & Berger, D.P. (2010a) Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. Journal of Clinical Oncology, 28, 437-444.
19. Kantarjian, H.M., Giles, F.J., Greenberg, P.L., Paquette, R.L., Wang, E.S., Gabrilove, J.L., Garcia-Manero, G., Hu, K., Franklin, J.L. & Berger, D.P. (2010b) Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood, 116, 3163-3170.
20. Kantarjian, H.M., Mufti, G.J., Fenaux, P., Sekeres, M.A., Szer, J., Platzbecker, U., Kuendgen, A., Gaidano, G., Wiktor-Jedrzejczak, W., Bennett, J.M., Meibohm, A., Yang, A.S. & Giagounidis, A. (2012) Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (Pts) with low or intermediate-1 (int-1) risk myelodysplastic syndrome (MDS): follow-up AML and survival results of a randomized, double-blind, placebo (PBO)-controlled study. Blood (ASH Annual Meeting Abstracts), 120, 421.
21. Manoharan, A., Brighton, T., Gemmell, R., Lopez, K., Moran, S. & Kyle, P. (2002) Platelet dysfunction in myelodysplastic syndromes: a clinicopathological study. International Journal of Hematology, 76, 272-278.
22. Mittelman, M. & Zeidman, A. (2000) Platelet function in the myelodysplastic syndromes. International Journal of Hematology, 71, 95-98.
23. Molineux, G. (2011) The development of romiplostim for patients with immune thrombocytopenia. Annals of the New York Academy of Sciences, 1222, 55-63.
24. Sekeres, M.A., Schoonen, W.M., Kantarjian, H., List, A., Fryzek, J., Paquette, R. & Maciejewski, J.P. (2008) Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. Journal of the National Cancer Institute, 100, 1542-1551.
25. Sekeres, M.A., Kantarjian, H., Fenaux, P., Becker, P., Boruchov, A., Guerci-Bresler, A., Hu, K., Franklin, J., Wang, Y.M. & Berger, D. (2011) Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer, 117, 992-1000.
26. Wang, E.S., Lyons, R.M., Larson, R.A., Gandhi, S., Liu, D., Matei, C., Scott, B., Hu, K. & Yang, A.S. (2012) A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology & Oncology, 5, 71.